Literature DB >> 25825217

Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.

Giuseppina Basta1, Serena Del Turco1, Teresa Navarra1, William M Lee2.   

Abstract

Animal studies suggest that receptor for advanced glycation end products (RAGE)-dependent mechanisms contribute to acetaminophen-induced liver damage. We examined whether circulating levels of soluble receptor for advanced glycation end products (sRAGE) or RAGE ligands, including extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE), high-mobility group box 1 (HMGB1), and Nε-(Carboxymethyl)lysine adducts (CML), could aid in prognostication after an acetaminophen overdose. Sixty well-characterized acetaminophen-related acute liver failure (ALF) patients (30 spontaneous survivors and 30 patients who underwent transplantation and/or died) who were enrolled in the National Institutes of Health-sponsored Acute Liver Failure Study Group, were matched by age, met standard criteria for encephalopathy, and had an international normalized ratio > 1.5 were retrospectively studied. HMGB1, EN-RAGE, CML, and sRAGE were detected by enzyme-linked immunosorbent assay methods in sera from ALF patients and 30 healthy controls. Levels of sRAGE, EN-RAGE, and HMGB1 (but not CML) were significantly greater (P < 0.001) in ALF patients versus normal controls. The levels of sRAGE, HMGB1, and EN-RAGE were significantly higher (P = 0.03, P < 0.01, and P = 0.03) in patients with a systemic inflammatory response syndrome (SIRS) score > 2 versus patients with a SIRS score ≤ 2. Nevertheless, only sRAGE levels were significantly higher in patients who underwent transplantation and/or died versus spontaneous survivors (P < 0.001), and they were positively associated with conventional markers of liver disease severity. Multivariate logistic regression identified an encephalopathy grade > 2 as an independent predictor of an adverse outcome on admission (odds ratio, 13; 95% confidence interval, 2.3-73; P < 0.001). The RAGE-ligand axis may interfere with liver regeneration and should be a promising objective for further research.
© 2015 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25825217      PMCID: PMC4933521          DOI: 10.1002/lt.24129

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  43 in total

1.  Soluble receptor for advanced glycation end products in patients with decreased renal function.

Authors:  Marta Kalousová; Magdaléna Hodková; Markéta Kazderová; Jana Fialová; Vladimír Tesar; Sylvie Dusilová-Sulková; Tomás Zima
Journal:  Am J Kidney Dis       Date:  2006-03       Impact factor: 8.860

2.  Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice.

Authors:  Udeme Ekong; Shan Zeng; Hao Dun; Nikki Feirt; Jiancheng Guo; Nikalesh Ippagunta; James V Guarrera; Yan Lu; Alan Weinberg; Wu Qu; Ravichandran Ramasamy; Ann Marie Schmidt; Jean C Emond
Journal:  J Gastroenterol Hepatol       Date:  2006-04       Impact factor: 4.029

3.  Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.

Authors:  Anne M Larson; Julie Polson; Robert J Fontana; Timothy J Davern; Ezmina Lalani; Linda S Hynan; Joan S Reisch; Frank V Schiødt; George Ostapowicz; A Obaid Shakil; William M Lee
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

Review 4.  Etiology and management of fulminant hepatic failure.

Authors:  Javier Vaquero; Andres T Blei
Journal:  Curr Gastroenterol Rep       Date:  2003-02

5.  Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice.

Authors:  Shan Zeng; Nikki Feirt; Michael Goldstein; James Guarrera; Nikalesh Ippagunta; Udeme Ekong; Hao Dun; Yan Lu; Wu Qu; Ann Marie Schmidt; Jean C Emond
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

6.  Blockade of receptor for advanced glycation end product attenuates pulmonary reperfusion injury in mice.

Authors:  David I Sternberg; Ram Gowda; Divya Mehra; Wu Qu; Alan Weinberg; William Twaddell; Joydeep Sarkar; Allison Wallace; Barry Hudson; Frank D'Ovidio; Selim Arcasoy; Ravichandran Ramasamy; Jeanine D'Armiento; Ann Marie Schmidt; Joshua R Sonett
Journal:  J Thorac Cardiovasc Surg       Date:  2008-08-29       Impact factor: 5.209

7.  S100A12 and soluble receptor for advanced glycation end products levels during human severe sepsis.

Authors:  Ahmed Achouiti; Dirk Föll; Thomas Vogl; Jan W O van Till; Pierre-François Laterre; Thierry Dugernier; Xavier Wittebole; Marja A Boermeester; Johannes Roth; Tom van der Poll; Marieke A D van Zoelen
Journal:  Shock       Date:  2013-09       Impact factor: 3.454

8.  Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure.

Authors:  Johannes Hadem; Penelope Stiefel; Matthias J Bahr; Hans L Tillmann; Kinan Rifai; Jürgen Klempnauer; Heiner Wedemeyer; Michael P Manns; Andrea S Schneider
Journal:  Clin Gastroenterol Hepatol       Date:  2008-03       Impact factor: 11.382

Review 9.  Acute liver failure in the United States.

Authors:  William M Lee
Journal:  Semin Liver Dis       Date:  2003-08       Impact factor: 6.115

10.  Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study.

Authors:  Massimo Miniati; Simonetta Monti; Giuseppina Basta; Franca Cocci; Edo Fornai; Matteo Bottai
Journal:  Respir Res       Date:  2011-03-30
View more
  5 in total

Review 1.  Contribution of RAGE axis activation to the association between metabolic syndrome and cancer.

Authors:  Ma Eugenia Garay-Sevilla; Armando Gomez-Ojeda; Ileana González; Claudia Luévano-Contreras; Armando Rojas
Journal:  Mol Cell Biochem       Date:  2021-01-04       Impact factor: 3.396

Review 2.  Biomarkers of drug-induced liver injury.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Adv Pharmacol       Date:  2019-03-06

3.  Therapeutic targets for liver regeneration after acute severe injury: a preclinical overview.

Authors:  Hidenobu Kojima; Kojiro Nakamura; Jerzy W Kupiec-Weglinski
Journal:  Expert Opin Ther Targets       Date:  2020-01-10       Impact factor: 6.902

Review 4.  The Role of Monocytes and Macrophages in Acute and Acute-on-Chronic Liver Failure.

Authors:  Evangelos Triantafyllou; Kevin J Woollard; Mark J W McPhail; Charalambos G Antoniades; Lucia A Possamai
Journal:  Front Immunol       Date:  2018-12-14       Impact factor: 7.561

Review 5.  COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?

Authors:  Serena Del Turco; Annamaria Vianello; Rosetta Ragusa; Chiara Caselli; Giuseppina Basta
Journal:  Thromb Res       Date:  2020-08-27       Impact factor: 3.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.